flortaucipir f-18
Drug data last refreshed 5d ago · AI intelligence enriched 2w ago
TAUVID (flortaucipir F-18) is an IV radiotracer diagnostic agent used in positron emission tomography (PET) imaging to detect tau pathology in the brain. It is indicated for imaging patients with cognitive impairment who may have Alzheimer's disease or related tauopathies. The drug enables clinicians to visualize and quantify tau accumulation, supporting diagnostic and prognostic assessment in neurodegenerative disease.
As a specialized diagnostic imaging product in peak lifecycle, TAUVID supports a focused commercial team with growth potential tied to adoption in memory care and neurology networks.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Careers on TAUVID center on diagnostic adoption, healthcare provider education, and payer engagement in a high-growth neurology space with limited competition. This is a specialized, technical role suited for professionals with imaging, neurology, or health economics expertise who can navigate hospital and imaging center channels.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/mo